CVKD — Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a biotechnology company listed on NASDAQ. It is led by Quang X. Pham, based in 822 A1A North, Ponte Vedra, FL, United States, 32082, with about 4 employees. Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. It has a collaboration agreement with Abbott Global Enterprises Limited to evaluate the efficacy and safety of Tecarfarin in patients with a left-ventricular assist device. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida.

Net income was -$2.7M. CVKD currently screens at market cap $20.2M.

Use this CVKD page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the CVKD quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the CVKD SEC filings page. Lician reads the product cache first so this HTML stays unique to Cadrenal Therapeutics, Inc. Common Stock even when a live quote feed is slow.